NeuroAct Communication offers expert guidance to scientific communication.

  • Define a publication strategy: identify objectives, target audience, journals
  • Aid to effective presentation of pharmacological data
  • Experienced scientific writing and editing: research reports, posters, symposia

For more information Contact.


5-HT1A receptors are involved in the effects of xaliproden on G-protein activation, neurotransmitter release and nociception. PDF

Martel JC, Assié MB, Bardin L, Depoortère R, Cussac D, Newman-Tancredi A.
Br J Pharmacol. 2009 Sep;158(1):232-42. Epub 2009 Jun 5.

Free full-text

BACKGROUND AND PURPOSE: Xaliproden (SR57746A) is a 5-HT1A receptor agonist and neurotrophic agent that reduces oxaliplatin-mediated neuropathy in clinical trials. The present study investigated its profile on in vitro transduction, neurochemical responses and acute nociceptive pain tests in rats. EXPERIMENTAL APPROACH: Xaliproden was tested on models associated with 5-HT1A receptor activation including G-protein activation, extracellular dopamine and 5-HT levels measured by microdialysis and formalin-induced pain. Activation of 5-HT1A receptors was confirmed by antagonism with WAY100635. KEY RESULTS: Xaliproden exhibited high affinity for rat (r) and human (h) 5-HT1A receptors (pKi= 8.84 and 9.00). In [35S]GTPgammaS (guanosine 5'-O-(3-[(35)S]thio)triphosphate) assays it activated both hippocampal r5-HT1A [pEC50/Emax of 7.58/61% (%5-HT)] and recombinant h5-HT1A receptors (glioma C6-h5-HT1A: 7.39/62%; HeLa-h5-HT1A: 7.24/93%). In functional [35S]GTPgammaS autoradiography, xaliproden induced labelling in structures enriched with 5-HT1A receptors (hippocampus, lateral septum, prefrontal and entorhinal cortices). Xaliproden inhibited in vivo binding of [3H]WAY100635 to 5-HT1A receptors in mouse frontal cortex and hippocampus (ID50: 3.5 and 3.3 mg/kg, p.o. respectively). In rat, it increased extracellular dopamine levels in frontal cortex and reduced hippocampal 5-HT levels (ED50: 1.2 and 0.7 mg/kg, i.p. respectively). In a rat pain model, xaliproden inhibited paw licking and elevation (ED50: 1 and 3 mg/kg, i.p. respectively) following formalin injection in the paw. All effects were reversed by pretreatment with WAY100635. CONCLUSIONS AND IMPLICATIONS: These results indicate that activation of 5-HT1A receptors is the principal mechanism of action of xaliproden and provide further support for the utility of 5-HT1A receptor activation as an anti-nociceptive strategy.